CYCS, cytochrome c, somatic, 54205

N. diseases: 67; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023530
Disease: Leukopenia
Leukopenia
0.010 Biomarker disease BEFREE Leucopenia occurred more often in the CYC group compared to the TwHF group (P = 0.034). 31713733 2020
CUI: C3495801
Disease: Granulomatosis with polyangiitis
Granulomatosis with polyangiitis
0.010 GeneticVariation disease BEFREE Although the use of glucocorticoids with CYC is the most common drug combination, no differences in the outcome of the pituitary function and GPA disease course are seen with other immunosuppressants. 31446541 2020
CUI: C0002965
Disease: Angina, Unstable
Angina, Unstable
0.010 Biomarker disease BEFREE Eighty-four consecutive type 2 diabetic patients with unstable angina (UA) were included from January 2018 to June 2018 to calculate calcification scores using computerized tomographic angiography (CTA), and the patients were divided into 2 groups: high calcification score group (HCS group) and low calcification score group (LCS group). 31452690 2019
CUI: C0004943
Disease: Behcet Syndrome
Behcet Syndrome
0.010 Biomarker disease BEFREE CYC remains an important treatment option for Behçet's syndrome (BS) patients with life-threatening manifestations. 31840168 2019
CUI: C0005859
Disease: Bloom Syndrome
Bloom Syndrome
0.010 Biomarker disease BEFREE We investigated short and long term adverse events associated with CYC use in BS patients. 31840168 2019
CUI: C0007965
Disease: Chediak-Higashi Syndrome
Chediak-Higashi Syndrome
0.010 Biomarker disease BEFREE We used two human CHS cell lines SW1353 and HCS-2/8 to analyze the expression profiles of ADAM8 in CHS cells compared with the normal chondrocytes. 31305294 2019
CUI: C0024143
Disease: Lupus Nephritis
Lupus Nephritis
0.010 Biomarker disease BEFREE Treatment with a combined immunosuppressive agent is superior to routine CYC only therapy in lupus nephritis. 30488367 2019
CUI: C0035334
Disease: Retinitis Pigmentosa
Retinitis Pigmentosa
0.010 Biomarker disease BEFREE <b>Abbreviations</b>: CYCS: cytochrome c; bRHO<sup>P23H</sup>: bovine RHO<sup>P23H</sup>; Cas9: CRISPR associated protein 9; dpf: days post-fertilization; eGFP: enhanced green fluorescent protein; GNAT1: guanine nucleotide-binding protein G(t) subunit alpha-1 aka rod alpha-transducin; HSPA1A/hsp70: heat shock protein of 70 kilodaltons; LAMP1: lysosomal-associated membrane protein 1; LC3: microtubule-associated protein 1A/1B light chain 3; mRFP: monomeric red fluorescent protein; RHO: rhodopsin; RP: retinitis pigmentosa; RPE65: retinal pigment epithelium-specific 65 kDa protein: sfGFP: superfolding GFP; sgRNA: single guide RNA; WGA: wheat germ agglutinin; <i>RHO<sub>p</sub></i>: the <i>Xenopus laevis RHO.2.L</i> promoter. 30975014 2019
CUI: C0042384
Disease: Vasculitis
Vasculitis
0.010 Biomarker disease BEFREE However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides. 31840168 2019
CUI: C0338451
Disease: Frontotemporal dementia
Frontotemporal dementia
0.010 Biomarker disease BEFREE <b>Abbreviations:</b> 4HPR: 4-hydroxy(phenyl)retinamide; AKT: AKT1 serine/threonine kinase 1; ALS: amyotrophic lateral sclerosis; ATG: autophagy related; AVs: autophagic vesicle; C9orf72: chromosome 9 open reading frame 72; CASP3: caspase 3; CHAT: choline O-acetyltransferase; CYCS: cytochrome c, somatic; DIV: day in vitro; FTD: frontotemporal dementia; FUS: FUS RNA binding protein; GFP: green fluorescent protein; hiPSCs: human induced pluripotent stem cells; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MNs: motoneurons; mRFP: monomeric red fluorescent protein; MTOR: mechanistic target of rapamycin kinase; NFE2L2/NRF2: nuclear factor, erythroid 2 like 2; RARA: retinoic acid receptor alpha; SLC18A3/VACHT: solute carrier family 18 (vesicular acetylcholine transporter), member 3; SQSTM1/p62: sequestosome 1; TBK1: TANK binding kinase 1; TEM: transmission electron microscopy. 30939964 2019
CUI: C1258104
Disease: Diffuse Scleroderma
Diffuse Scleroderma
0.010 Biomarker disease BEFREE We concluded that i.v.CYC pulse therapy should be considered as an effective treatment option for skin thickening in dcSSc patients, because 43% of this group of patients were found to have a clinically relevant response. 31628802 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 Biomarker phenotype BEFREE Then, by silencing or overexpressing ADAM8, the effects on cell migration and invasion in SW1353 and HCS-2/8, and the downstream signal transduction pathways were evaluated. 31305294 2019
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
0.010 Biomarker disease BEFREE Overall outcomes were comparable to those of two matched cohorts (n = 172) from previous European Vasculitis Society (EUVAS) trials, but with lower total exposure to CYC and GCs (P < 0.001) and reduced rates of severe infections (P = 0.02) compared with the RITUXVAS (rituximab versus cyclophosphamide in AAV) trial. 30239910 2019
CUI: C0018671
Disease: Head and Neck Neoplasms
Head and Neck Neoplasms
0.010 Biomarker group BEFREE In this chapter, we describe the HCS assay methods to measure IL-6-induced STAT3 signaling pathway activation in head and neck tumor cell lines as revealed by the expression and subcellular distribution of pSTAT3-Y705, pSTAT3-S727, and U-STAT3. 29082496 2018
CUI: C0037285
Disease: Skin Manifestations
Skin Manifestations
0.010 Biomarker phenotype BEFREE The aim of the study was to compare the efficacy and safety of RTX compared with CYC in retarding the progression of interstitial lung disease and skin manifestations of primary SSc. 30053212 2018
CUI: C0340613
Disease: Arterial aneurysm
Arterial aneurysm
0.010 Biomarker disease BEFREE CYC and high dose glucocorticoids decreased mortality in pulmonary arterial aneurysms and postoperative complications in peripheral artery aneurysms. 30107448 2018
CUI: C0677932
Disease: Progressive Neoplastic Disease
Progressive Neoplastic Disease
0.010 Biomarker phenotype BEFREE Progressive disease that was unresponsive to augmented immunosuppression with CYC was seen in five patients. 29562252 2018
CUI: C0751356
Disease: Idiopathic Inflammatory Myopathies
Idiopathic Inflammatory Myopathies
0.010 Biomarker disease BEFREE We report the first cohort study of PO CYC use in IIM patients with severe, treatment refractory disease. 29971584 2018
CUI: C3539781
Disease: Progressive cGVHD
Progressive cGVHD
0.010 Biomarker disease BEFREE Progressive disease that was unresponsive to augmented immunosuppression with CYC was seen in five patients. 29562252 2018
CUI: C4048329
Disease: Immunosuppression
Immunosuppression
0.010 Biomarker disease BEFREE Progressive disease that was unresponsive to augmented immunosuppression with CYC was seen in five patients. 29562252 2018
CUI: C0014060
Disease: Encephalitis, St. Louis
Encephalitis, St. Louis
0.010 Biomarker disease BEFREE Two subcohorts of treated SLE patients were defined on the basis of treatment with antimalarials (n = 1942) and other immunosuppressants (AZA, CYC, ciclosporin, MTX, MMF or rituximab; n = 2175). 28039412 2017
Secondary malignant neoplasm of bone
0.010 Biomarker disease BEFREE In this review, we will highlight the macrophage functions in the skeleton, in the maintenance of the HCS niches, and their importance in bone metastasis. 28247013 2017
Cervical intraepithelial neoplasia grade 2
0.010 AlteredExpression disease BEFREE In addition, the transcription of PCBP2, MCM5, hnRNPA1, TYPH, and CYC was also significantly increased in cervical intraepithelial neoplasia II-III compared to normal cervix. 28443473 2017
CUI: C0010691
Disease: Cystinuria
Cystinuria
0.010 Biomarker disease BEFREE The affected siblings display a recognizable phenotype which is similar to atypical HCS with regard to growth failure and neuro-muscular features, but is characterized by lack of cystinuria. 23794250 2013
CUI: C0015544
Disease: Failure to Thrive
Failure to Thrive
0.010 Biomarker disease BEFREE The affected siblings display a recognizable phenotype which is similar to atypical HCS with regard to growth failure and neuro-muscular features, but is characterized by lack of cystinuria. 23794250 2013